Evercore ISI Group analyst Mark Mahaney maintains Meta Platforms (NASDAQ:META) with a Outperform and raises the price target from $170 to $275.
Zentalis Pharmaceuticals To Highlight Preclinical Data Demonstrating That WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-Tumor Activity With KRAS(G12C) Inhibitors At AACR Annual Meeting 2024
Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of
